Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Skye Bioscience, Inc. (SKYE : NSDQ)

• Company Description    Skye Bioscience Inc. is a biopharmaceutical company. It is focused on developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need. Skye Bioscience Inc., formerly known as Emerald Bioscience Inc., is based in San Diego, Calif. Number of Employees: 16

• Price / Volume Information    Yesterday's Closing Price: $3.98 Daily Weekly Monthly 20 Day Moving Average: 2,147,082 shares Shares Outstanding: 30.98 (millions) Market Capitalization: $123.28 (millions) Beta: 1.95 52 Week High: $7.25 52 Week Low: $1.14 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 94.15% 85.38% 12 Week 177.35% 134.06% Year To Date 40.64% 32.14%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 11250 EL CAMINO REAL SUITE 100 - SAN DIEGO,CA 92130 USA ph: 858-410-0266 fax: - ir@skyebioscience.com http://www.skyebioscience.com

• General Corporate Information    Officers Punit Dhillon - Chief Executive Officer; Chairman and Director Paul Grayson - Chairman;Director Kaitlyn Arsenault - Chief Financial Officer Deborah Charych - Director Andrew J. Schwab - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 83086J200 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/08/25 Share - Related Items Shares Outstanding: 30.98 Most Recent Split Date: 9.00 (0.00:1) Beta: 1.95 Market Capitalization: $123.28 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.35 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.31 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/08/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.08 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -55.56% vs. Previous Quarter: -16.67% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - -53.92 12/31/24 - -42.10 ROA 06/30/25 - - 03/31/25 - -48.58 12/31/24 - -37.00 Current Ratio 06/30/25 - - 03/31/25 - 11.85 12/31/24 - 16.32 Quick Ratio 06/30/25 - - 03/31/25 - 11.85 12/31/24 - 16.32 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - 1.91 12/31/24 - 2.25 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©